Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Free Cash Flow: 2023-2025

Historic Free Cash Flow for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$32.8 million.

  • NewAmsterdam Pharma Co N.V's Free Cash Flow fell 160.88% to -$32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.5 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$159.2 million for FY2024, which is 12.74% down from last year.
  • NewAmsterdam Pharma Co N.V's Free Cash Flow amounted to -$32.8 million in Q3 2025, which was up 13.10% from -$37.8 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Free Cash Flow's 5-year high stood at -$12.6 million during Q3 2024, with a 5-year trough of -$55.0 million in Q1 2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Free Cash Flow value was -$36.5 million (recorded in 2025), while the average stood at -$37.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 73.23% in 2024, then tumbled by 160.88% in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Free Cash Flow stood at -$33.1 million in 2023, then dropped by 13.32% to -$37.5 million in 2024, then slumped by 160.88% to -$32.8 million in 2025.
  • Its Free Cash Flow stands at -$32.8 million for Q3 2025, versus -$37.8 million for Q2 2025 and -$36.5 million for Q1 2025.